Statins under California Prop 65

Executive Summary

California's Office of Environmental Health Hazard Assessment should assess toxicological studies on each member of the statin class of cholesterol drugs, California Carcinogen Committee recommended at Dec. 17 meeting. OEHHA will present to committee on consideration of each drug for placement on Proposition 65 carcinogen list at 2003 or 2004 annual meeting. Merck's Mevacor (lovastatin) was picked for consideration at random, but Merck petitioned committee to consider the statins as a group (1"The Pink Sheet" Dec. 9, 2002, p. 22)...